NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…
Search results for: psoriasis

Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass
Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…

The 2021 ACR Awards of Distinction & Distinguished Fellows
During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…

Care of Patients with Spondyloarthritis
At the ACR Convergence session CARE: Spondyloarthritis, Alexis Ogdie, MD, presented key principles of diagnosis & management of patients with spondyloarthritis.

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session
Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

Updates in Osteoarthritis: Research Provides Insights into Molecular Pathogenesis of OA
In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Guselkumab Boosts Response in Resistant Psoriatic Arthritis
NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the…

The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Anti-SAE Identifies a Subtype of Dermatomyositis
Albayda et al. describes a North American cohort of patients with dermatomyositis, reporting that small ubiquitin-like modifier activating enzyme (SAE) autoantibodies are clearly associated with this clinical disease. Patients with this clinical phenotype most commonly present with a rash first, followed by muscle involvement.
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 55
- Next Page »